The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).
 
Darren R. Feldman
Research Funding - Novartis; Seagen
 
Marion Feuilly
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Jie Meng
Employment - Analytica Laser
Research Funding - Abbvie (Inst); Chimerix (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Johanna Lister
Employment - Analytica Laser
Research Funding - AbbVie; Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Florence Marteau
Employment - Ipsen
 
Michael J. Morris
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; Bayer; Blue Earth Diagnostics; Endocyte; Tokai Pharmaceuticals; Tolmar
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Endocyte
 
Daniel J. George
Honoraria - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Ipsen; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)